Inflammatory Markers and Adverse Outcomes in Chronic Kidney Disease (AIMtoPREVENT)

Institute of Kidney Lifescience Technologies

Status: Completed

Conditions: Chronic Kidney Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01974713

042010

Details and patient eligibility

About

Longitudinal cohort of patients with chronic kidney disease followed in 3 kidney centers in Ontario. The goal is to determine whether and how rates of renal disease progression are affected by inflammatory markers, FGF23 levels, and genetic polymorphisms

Full description

This longitudinal cohort study will follow 2500 prevalent Chronic Kidney Disease (CKD)patients under the care of a nephrologist at 3 Southern Ontario Nephrology centres and all affiliated satellite centres with an estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min to determine the rate of their renal disease progression over a 36 months. All CKD patients older than 18 years of age may be included in this study. This study will analyze, with 6 month serial measurements, conventional biochemical, hormonal and metabolic parameters in addition to the demographics, clinical status, medications and blood and urine samples of these patients. This study will assess the influence of inflammation on FGF23 and genetic polymorphisms that may reflect the processes involved with disease progression.

Enrollment: 2,530 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients referred to a nephrologist for evaluation of CKD or those currently seen by a nephrologist, with eGFR less than 60 ml/min
• Patients that are erythropoietin treatment naive
• Transplant patients with failing grafts requiring nephrologists follow-up
• Patients currently not receiving RRT consenting to be in the study
• Adults 18 years of age and older

Exclusion criteria

• Functioning Organ transplant
• Life expectancy less than 12 months
• Patients currently receiving RRT or who will likely initiate RRT within 6 months
• Patients unable or contraindicated to receive EPREX® as erythropoietin replacement therapy for the correction of anemia related to CKD